An interventional study of EVOLUT R/PRO/PRO+/FX bioprosthesis and Edwards Sapien S3/Ultra bioprosthesis in Valve Heart Disease, sponsored by Erasmus Medical Center. Recruiting at 14 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Heart Valve Diseases with a site in Germany — 18 open to participants now, 24 under way, none of them phase 3. Heart Valve Diseases · Germany.
Among the 65 studies in Heart Valve Diseases with a site in Germany, this one is the 8th largest by planned enrollment of the 35 interventional ones that give a count, is one of 8 that started in 2021, is one of 32 with no phase, reaches primary completion later than 17 of the 23 other live ones, and was the 48th registered.
557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.
Browse Heart Valve Diseases studies →18 of the 65 studies in Heart Valve Diseases with a site in Germany are open now. Recruiting first, the newest first:
Edwards Lifesciences · Sites in Germany, Greece, Italy and 3 more countries
TRiCares · Sites in Germany, Belgium
Ages 18+
Abbott Medical Devices · Sites in Germany, United States, Denmark and 7 more countries
Montreal Heart Institute · Sites in Germany, United States, Canada and 2 more countries
Ages 18+
LMU Klinikum · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 100 across 314 interventional studies indexed under Heart Valve Diseases.
Median enrollment 180 across the 35 interventional studies, 300 across the 30 observational. Of the 36 that completed or were terminated, 19 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 65 have an industry lead sponsor. The 10 most frequent:
Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Erasmus Medical Center has 3 studies filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
3 of the studies in Heart Valve Diseases with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03339115Cardiovalve Ltd.AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System | 2026-12-31 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT06634121LMU KlinikumEfficacy of MitraCLip Vs. PASCAL for the TrEAtment of MitraL REgurgiTation in an All-comer Population | 2027-04-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies in Heart Valve Diseases with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Transcatheter aortic valve implantation (TAVI) serves a growing spectrum of patients with symptomatic severe aortic stenosis (AS). Approximately 80% of surgical aortic valve replacements are performed using a bioprosthesis. Durability of surgical bioprostheses varies according to patient age at the time of implantation, prosthesis type and size, among other factors. TAVI has become an established treatment option for patients with a degenerated surgical aortic bioprosthesis. The time from index surgical aortic valve replacement (SAVR) to bioprosthetic valve degeneration is typically 8-10 years. TAVI in this setting has shown favorable outcomes. Balloon-expandable and self-expanding transcatheter heart valves (THVs) can both be used for the treatment of a degenerated surgical aortic bioprosthesis and have specific advantages and limitations. Valve-in-valve TAVI may be associated with coronary obstruction, THV migration, paravalvular regurgitation, and prosthesis-patient mismatch.
Objective:
To compare valve-in-valve TAVI with balloon-expandable SAPIEN/MYVAL THV series versus the self-expanding EVOLUT THV series. The primary analysis evaluates device success at 30 days in the primary cohort. Continued enrollment will additionally support a secondary comparison of the safety and efficacy of the SAPIEN and MYVAL THV series.
Study design: International multicenter randomized study with 1:1 randomization to TAVI with the EVOLUT THV series or the SAPIEN/MYVAL THV series.
Study population:
The primary cohort comprises 440 patients with a failing surgical aortic bioprosthesis (aortic stenosis with or without aortic regurgitation) selected for transfemoral TAVI by heart-team consensus. Enrollment of the primary cohort has been completed.
The continued-enrollment cohort comprises 160 additional patients and will increase the total study population to 600 patients, with a target distribution of 300 patients treated with the EVOLUT THV series, 150 with the SAPIEN THV series, and 150 with the MYVAL THV series.
Investigational intervention:
Transfemoral valve-in-valve TAVI with a balloon-expandable SAPIEN or MYVAL THV series or a self-expanding EVOLUT THV series.
Main study parameters/endpoints:
Primary endpoint is device success at 30 days
Defined by:
Severe prosthesis-patient mismatch is defined as an indexed effective orifice area (EOAi) ≤0.65 cm²/m² (≤0.55 cm²/m² if BMI ≥30 kg/m²).
The continued-enrollment cohort is designed to support this comparison.
The criteria were revised on the registry on Oct 13, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study subjects will receive a self-expanding valve from the EVOLUT THV series (EVOLUT R/PRO/PRO+/FX).
Device: EVOLUT R/PRO/PRO+/FX bioprosthesis
Study subjects will receive a balloon-expandable valve from either the SAPIEN THV series (SAPIEN 3, SAPIEN 3 Ultra) or the MYVAL THV series (Myval Octacor, Myval Octapro).
Device: Edwards Sapien S3/Ultra bioprosthesis · Device: MYVAL/Octacor/Octapro bioprosthesis
To compare EVOLUT R/PRO/PRO+/FX bioprosthesis versus Edwards SAPIEN 3/Ultra bioprosthesis or Myval/Octacor/ Octapro in failing surgical bioprostheses
Edwards Sapien S3/Ultra bioprosthesis
MYVAL/Octacor/Octapro bioprosthesis
Device success
Defined by: * Absence of procedural mortality; AND * Technical success at exit from the procedure room defined as freedom from mortality, successful access, delivery of the device and retrieval of the delivery system, correct positioning of a single prosthetic heart valve into the proper anatomical location, and freedom from surgery or intervention related to the device or to a major vascular or access-related, or cardiac structural complication; AND * Intended performance of the prosthetic heart valve (no severe prosthesis-patient mismatch and mean aortic valve gradient \<20 mmHg or peak velocity \<3 m/s, Doppler velocity index ≥0.25, and no moderate or severe prosthetic valve regurgitation). Severe prosthesis-patient mismatch is defined as an indexed effective orifice area (EOAi) ≤0.65 cm²/m² (≤0.55 cm²/m² if BMI ≥30 kg/m²).
Time frame: 30 days post transcatheter valve implantation
Composite of all-cause death, disabling stroke, rehospitalization for heart failure or valve related problems
Safety endpoint
Time frame: 1 year post transcatheter valve implantation
Moderate or severe prosthesis-patient mismatch
Moderate or severe prosthesis-patient mismatch is defined as EOAi ≤0.85 cm²/m² (≤0.70 cm²/m² if BMI ≥30 kg/m²). This endpoint will be compared between patients treated with the SAPIEN and MYVAL THV series.
Time frame: 30 days post transcatheter valve implantation
Plan to share: No
Started May 2021 (actual). Primary completion is estimated for Jun 2028, 85 months after the start.
Of 108 non-industry interventional studies with no phase under Heart Valve Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 85 months is above that.
Counting every sponsor, half of 154 studies reached it within 30 months; a quarter within 16 and three quarters within 55.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion May 2026 → Jun 2028 and completion May 2026 → May 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.